PortfoliosLab logo
Biocept, Inc. (BIOC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US09072V5012

CUSIP

09072V501

IPO Date

Feb 5, 2014

Highlights

Market Cap

$1.14M

EPS (TTM)

-$48.17

PEG Ratio

-0.04

Target Price

$4.00

Short %

0.57%

Short Ratio

0.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


BIOC

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of BIOC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20234.91%-6.29%-34.74%-20.59%-73.33%-43.98%-3.31%-26.50%45.35%-75.20%-80.97%18.31%-99.56%
2022-22.65%-14.64%-2.93%-32.76%-8.97%-33.80%4.53%4.82%-10.55%-13.17%-3.75%-31.17%-85.36%
202132.21%2.73%-15.59%-6.09%-5.44%-7.30%-2.39%-11.49%10.77%-7.23%6.18%-8.35%-18.47%
20207.83%152.92%-66.03%45.21%13.05%63.56%4.29%-10.38%-33.68%-2.04%6.94%-3.90%55.24%
2019129.04%-47.72%11.65%-20.87%34.07%-9.02%-9.01%-12.87%-7.66%-12.31%-25.64%-46.03%-66.75%
2018-51.43%3.86%-15.71%-35.93%14.81%-7.83%-20.00%-26.67%-21.88%-30.91%-44.21%-18.86%-95.87%
201784.64%43.36%3.90%-23.94%-7.41%-8.67%1.46%-12.23%0.82%-28.45%-18.19%-3.62%-10.41%
20162.90%-5.63%-3.73%-23.25%-36.31%5.46%-2.26%-11.08%-9.46%-45.22%2.33%-11.99%-81.29%
20150.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-96.27%-96.27%
20140.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Biocept, Inc. (BIOC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Biocept, Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


Biocept, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Biocept, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biocept, Inc. was 100.00%, occurring on Dec 20, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Dec 17, 20152016Dec 20, 2023

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biocept, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Biocept, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -354.2%.


-1.000.001.002.003.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023April
3.50
0
Actual
Estimate

Valuation

The Valuation section provides an overview of how Biocept, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BIOC compared to other companies in the Diagnostics & Research industry. BIOC currently has a PEG ratio of -0.0. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BIOC relative to other companies in the Diagnostics & Research industry. Currently, BIOC has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BIOC in comparison with other companies in the Diagnostics & Research industry. Currently, BIOC has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items